1. Home
  2. TDF vs AGEN Comparison

TDF vs AGEN Comparison

Compare TDF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Dragon Fund Inc.

TDF

Templeton Dragon Fund Inc.

HOLD

Current Price

$10.74

Market Cap

268.9M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.50

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TDF
AGEN
Founded
1994
1994
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.9M
274.8M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
TDF
AGEN
Price
$10.74
$7.50
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
55.9K
8.3M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.75
Revenue Growth
N/A
89.95
52 Week Low
$10.15
$2.71
52 Week High
$12.20
$8.70

Technical Indicators

Market Signals
Indicator
TDF
AGEN
Relative Strength Index (RSI) 50.66 80.52
Support Level $10.33 $2.97
Resistance Level $11.29 $8.70
Average True Range (ATR) 0.27 0.66
MACD 0.01 0.25
Stochastic Oscillator 51.75 96.55

Price Performance

Historical Comparison
TDF
AGEN

About TDF Templeton Dragon Fund Inc.

Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: